Postoperative acute pain
Conditions
Interventions
Control group 1:40 ml of 0.375% ropivacaine combined with 2 mg of dexamethasone were used for postoperative analgesia, 20 ml of bilateral rectus abdominis sheath block, and 15 ml of local infiltration
Control group 2:Postoperative analgesia was performed with 40 ml of 0.665% bupivacaine liposome combined with 2 mg of dexamethasone for rectus abdominis sheath block, 20 ml for bilateral rectus abdomi
Experimental group:Postoperative analgesia was performed with 40 ml of 0.665% bupivacaine liposome for rectus abdominis sheath block, 20 ml for bilateral rectus abdominis sheath block, and 15 ml for l
Sponsors
The First Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Patients who intend to undergo elective laparoscopic radical gastrectomy for the same group of doctors; 2) Male or female, age 18-75 years old; 3) Male weight >=50kg, female weight >=45kg, BMI 19.0~26.0kg/m^2; 4) Anesthesia ASA rating is I~III; 5) Understand the nature, significance, possible benefits, possible inconveniences and potential dangers of the trial in detail before the trial, understand the research procedures and voluntarily sign the informed consent form in writing.
Exclusion criteria
Exclusion criteria: 1) Patient refuses rectus sheath block; 2) Patient has a specific allergic disease (asthma, urticaria, eczema, etc.) or is known to be allergic to bupivacaine; 3) There is a break or infection in the abdominal wall area of the patient; 4) The patient's coagulation function was abnormal, and the patient's preoperative APTT>33.8S or PT>12.1S (33.8 and 12.1 were the reference intervals set by the laboratory department of our hospital according to the current normal control values of 25.2 and 10.9, and if the normal control values changed, the reference intervals would also change accordingly); 5) The patient has a history of chronic neuropathic pain in the past; 6) Patients participate in other clinical trials at the same time.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total perioperative opioid use; | — |
Secondary
| Measure | Time frame |
|---|---|
| Resting NRS-R pain score;NRS-M pain score during exercise;QoR-15 scale score;Time of first postoperative exhaust defecation;Cytokines (TNF-a, IL-1ß, and IL-6);Blood concentration of bupivacaine;Incidence of postoperative nausea and vomiting and the use of antiemetic drugs;Postoperative hospital stay;Hospitalization expenses;PACU residence time;Time of first emergency analgesic drug use;Tracheal intubation removal time;First time out of bed activity;Incidence of local anesthetics adverse reaction events;Incidence of adverse events during nerve block procedures; | — |
Countries
China
Contacts
Public ContactChen Shibiao
The First Affiliated Hospital of Nanchang University
Outcome results
None listed